-
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-04-16 Debasis Sen, Sunny Rathee, Vishal Pandey, Sanjay K. Jain, Umesh K. Patil
: Alzheimer's disease [AD] is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairment. Despite extensive research, the exact etiology remains elusive. This review explores the multifaceted pathophysiology of AD, focusing on key hypotheses such as the cholinergic hypothesis, hyperphosphorylated Tau Protein and Amyloid β hypothesis, oxidative
-
Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-04-16 Subha Kalyaanamoorthy, Stanley Kojo Opare, Xiaoxiao Xu, Aravindhan Ganesan, Praveen P.N. Rao
:: Microtubule-Associated Protein Tau (also known as tau) has been shown to accumulate into paired helical filaments and neurofibrillary tangles, which are known hallmarks of Alzheimer’s disease (AD) pathology. Decades of research have shown that tau protein undergoes extensive post-translational modifications (PTMs), which can alter the protein's structure, function, and dynamics and impact the various
-
The Postoperative Effects of Anesthesia Exposure on Cognitive Decline in Older Adults: A Narrative Review Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-04-16 Kathleen Angela Willoughby-Dudley, Marielle L. Darwin, Deana B. Davalos
Background:: As modern medicine continues to make strides in effective surgical treatments, we must also consider the critical impact of anesthesia on neuropsychological outcomes. Recent evidence suggests that anesthesia exposure may be a risk factor for postoperative cognitive decline and the eventual development of dementia. Objectives:: To explore the vulnerability of the aging brain in the context
-
Evaluation and Characterization of Modified K114 Method to Localize Plaques in Rodent and Plaques and Tangles in Human Brain Tissue Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-04-03 Sanjana Padala, Sharay Setti, James Raymick, Joseph Hanig, Sumit Sarkar
Background: A plethora of studies has shown the utility of several chemical dyes due to their affinity to bind Aβ to enable visualization of plaques under light or fluorescence microscope, and some of them showed affinity to bind neurofibrillary tangles (NFT) as well. However, only a few of them have the propensity to bind both senile plaques (SP) and NFT simultaneously. Objective: In our current study
-
Disruptions of Gut Microbiota are Associated with Cognitive Deficit of Preclinical Alzheimer's Disease: A Cross-Sectional Study Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-25 Binbin Yu, Guomeng Wan, Shupeng Cheng, Pengcheng Wen, Xi Yang, Jiahuan Li, Huifang Tian, Yaxin Gao, Qian Zhong, Jin Liu, Jianan Li, Yi Zhu
Background: Alzheimer's Disease (AD) is the most prevalent type of dementia. The early change of gut microbiota is a potential biomarker for preclinical AD patients. Objective: The study aimed to explore changes in gut microbiota characteristics in preclinical AD patients, including those with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), and detect the correlation between
-
Plant Soup Formulations Show Cholinesterase Inhibition Potential in the Prevention of Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-25 Dorota Gajowniczek-Ałasa, Dominik Szwajgier, Ewa Baranowska-Wójcik
Background: As the cholinesterase theory is a prominent hypothesis underlying our current understanding of Alzheimer's disease (AD), the goal of this study was to compose functional vegan lunchtime soups with potential health benefits in the prevention of AD (in the context of cholinesterase inhibition). Materials and Methods:: The potential of 36 edible plant raw materials in terms of acetyl- and
-
Beyond Conventional Therapies: Molecular Dynamics of Alzheimer's Treatment through CLOCK/BMAL1 Interactions Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-19 Ismail Celil Haskologlu, Emine Erdag, Ahmet Ozer Sehirli, Orhan Uludag, Nurettin Abacioglu
Background: Alzheimer's Disease (AD) represents a neurodegenerative disorder characterized by cognitive and behavioral impairments significantly hindering social and occupational functioning. Melatonin, a hormone pivotal in regulating the body's intrinsic circadian rhythm, also acts as a catalyst in the breakdown of beta-amyloid deposits, offering a promising therapeutic approach for AD. The upregulation
-
Research Progress of Mitophagy in Alzheimer's Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-12 Jinglin Yao, Bohong Kan, Zhengjia Dong, Zhenyu Tang
The prevalence of Alzheimer's disease (AD) is increasing as the elderly population, which hurts elderly people's cognition and capacity for self-care. The process of mitophagy involves the selective clearance of ageing and impaired mitochondria, which is required to preserve intracellular homeostasis and energy metabolism. Currently, it has been discovered that mitophagy abnormalities are intimately
-
A Review on the Use of Modern Computational Methods in Alzheimer’s Disease-Detection and Prediction Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-08 Arka De, Tusar Kanti Mishra, Sameeksha Saraf, Balakrushna Tripathy, Shiva Shankar Reddy
Discoveries in the field of medical sciences are blooming rapidly at the cost of voluminous efforts. Presently, multidisciplinary research activities have been especially contributing to catering cutting-edge solutions to critical problems in the domain of medical sciences. The modern age computing resources have proved to be a boon in this context. Effortless solutions have become a reality, and thus
-
Drug Design for Alzheimer’s Disease: Biologics vs. Small Molecules Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-08 Donald Weaver
There shall probably be no “magic bullet” for Alzheimer’s; rather, we should be pursuing a “magic shotgun blast” that will target multiple complementary therapeutic receptors. Although protein misfolding/oligomerization will probably be one of these targets, this alone is insufficient and will require the co-administration of other therapeutic entities engaging targets, such as immunopathy, gliopathy
-
Nanostructured Lipid Carriers of Donepezil Hydrochloride for the Treatment of Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-06 Avinash Tekade, Ram Susar, Gajanan Kulkarni, Samiksha Surwade, Anil Gaikwad
Background: Alzheimer's Disease (AD) is a long-term brain disorder that worsens over time. A cholinesterase inhibitor called Donepezil HCl (DNZ) is used to treat and control AD. Due to its failure to reach the appropriate concentration in the brain cells, its efficacy upon oral administration is limited, and thus investigation of alternative administration route is necessary. Objective: The objective
-
Multimodal Gamma Stimulation Improves Activity but not Memory in Aged Tgf344-AD Rats Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-05 J.H. Bentley, J.I. Broussard
Background: Multimodal sensory gamma stimulation is a treatment approach for Alzheimer’s disease that has been shown to improve pathology and memory in transgenic mouse models of Alzheimer's. Because rats are closer to humans in evolution, we tested the hypothesis that the transgenic rat line bearing human APP and PS1, line TgF344-AD, would be a good supplemental candidate to test the efficacy of this
-
Exploring Potential of Nano-formulations in the Treatment of Alzheimer’s Disease through Nasal Route Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-03-01 Avinash Tekade, Prasad Kadam, Sachin Jagdale, Samiksha Surwade, Anil Gaikwad, Parth Pawar, Rushikesh Shinde
Objective:: Alzheimer's disease, a progressive neurodegenerative disorder, severely impacts cognitive function and daily living. The current treatment provides only symptomatic relief, and thus, disease-modifying therapies targeting underlying causes are needed. Although several potential therapies are in various stages of clinical trials, bringing a new Alzheimer's drug to market remains challenging
-
Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-28 Carlos Platero, Jussi Tohka, Bryan Strange
Background: Mild Cognitive Impairment (MCI) usually precedes the symptomatic phase of dementia and constitutes a window of opportunities for preventive therapies. Objectives: The objective of this study was to predict the time an MCI patient has left to reach dementia and obtain the most likely natural history in the progression of MCI towards dementia. Methods: This study was conducted on 633 MCI
-
Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-28 Zuber Khan, Sidharth Mehan, Mohd. Anas Saifi, Ghanshyam Das Gupta, Acharan S. Narula, Reni Kalfin
Dementia, an international health issue distinguished by the impairment of daily functioning due to cognitive decline, currently affects more than 55 million people worldwide, with the majority residing in low-income and middle-income countries. Globally, dementia entails significant economic burdens in 2019, amounting to a cost of 1.3 trillion US dollars. Informal caregivers devote considerable hours
-
Handwriting Markers for the Onset of Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-28 Yury Chernov
Introduction: Alzheimer's disease has an impact on handwriting (AD). Numerous researchers reported that fact. Therefore, examining handwriting characteristics could be a useful way to screen for AD. The aim of the article is to present the reliability and effectiveness of the AD-HS tool. Method: Most of the existing studies examine either linguistic manifestations of writing or certain motor functions
-
Antipsychotics in Alzheimer’s Disease: Current Status and Therapeutic Alternatives Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-27 Maria Paula Maziero, Natalia P. Rocha, Antonio L. Teixeira
: Psychosis and hyperactive behaviors, such as agitation and wandering, affect a significant proportion of patients with Alzheimer’s disease (AD). These symptoms are often treated with antipsychotics, usually in an off-label approach. This mini-review provides an updated perspective on the pharmacological approach for the neuropsychiatric symptoms (NPS) in AD. The results of new studies have provided
-
Association Between Cannabis Use and Subjective Cognitive Decline: Findings from the Behavioral Risk Factor Surveillance System (BRFSS) Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-23 Zhi Chen, Roger Wong
Background: Cannabis consumption has rapidly increased in the United States due to more states legalizing non-medical and medical use. There is limited research, however, investigating whether cannabis may be associated with cognitive function, particularly across multiple dimensions of cannabis use. Objective: The objective of this study was to examine whether cannabis consumption reason, frequency
-
Alzheimer's Disease and Suicide: An Integrative Literature Review Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-22 Juliano Flávio Rubatino Rodrigues, Livia Peregrino Rodrigues, Gerardo Maria de Araújo Filho
Introduction: Suicide has been described in patients with Alzheimer's disease. Some promising medications for treating Alzheimer's disease have had their studies suspended because they increase the risk of suicide. Understanding the correlations between suicide and Alzheimer's disease is essential in an aging world. Method: A search was carried out on electronic websites (PubMed and Scielo) using the
-
The Association of Allergy-Related and Non-Allergy-Related Olfactory Impairment with Cognitive Function in Older Adults: Two Cross- Sectional Studies Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-21 Hui Chen, Yihong Ding, Liyan Huang, Wansi Zhong, Xiaojun Lin, Baoyue Zhang, Yan Zheng, Xin Xu, Min Lou, Changzheng Yuan
Background: Evidence on the association of Olfactory Impairment (OI) with age-related cognitive decline is inconclusive, and the potential influence of allergy remains unclear. Objective: We aimed to evaluate the cross-sectional associations of allergy-related and non-allergy- related OI to cognitive function. Methods: We included 2,499 participants from the Health and Retirement Study (HRS)-Harmonized
-
Toxic Advanced Glycation End-Products-Dependent Alzheimer’s Disease- Like Alternation in the Microtubule System Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-14 Hayahide Ooi, Yoshiki Koriyama
Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's Disease (AD). However, the detailed mechanism underlying T2DM-related AD remains unknown. In DM, many types of advanced glycation end-products (AGEs) are formed and accumulated. In our previous study, we demonstrated that Glyceraldehyde (GA)-derived Toxic Advanced Glycation End-products (Toxic AGEs, TAGE) strongly showed cytotoxicity
-
Microglia PTK2B/Pyk2 in the Pathogenesis of Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-02-06 Yun Guo, Cheng-Kun Sun, Lian Tang, Meng-Shan Tan
Alzheimer’s disease (AD) is a highly hereditary disease with complex genetic susceptibility factors. Extensive genome-wide association studies have established a distinct susceptibility link between the protein tyrosine kinase 2β (PTK2B) gene and late-onset Alzheimer’s disease (LOAD), but the specific pathogenic mechanisms remain incompletely understood. PTK2B is known to be expressed in neurons, and
-
Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer’s Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-01-30 YongSoo Shim
Background and Objective: Recent evidence suggests that blood-based biomarkers might be useful for Alzheimer’s disease (AD). Among them, we intend to investigate whether neurofilament light (NfL) and multimer detection system-oligomeric Aβ (MDS-OAβ) values can be useful in screening, predicting, and monitoring disease progression and how the relationship between NfL and MDS-OAβ values changes. Methods:
-
Association of Autoimmune Disorders and Disease-modifying Antirheumatic Drugs: (DMARDs) with the Risk of Alzheimer’s and/or Dementia: A Population Study Using Medicare Beneficiary Data Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-01-26 Qian Ding, Jennifer Lamberts, Alison M. Konieczny, Tyler B. Bringedahl, Kiara Y. Torres Garcia
Objectives: Alzheimer’s disease (AD) and/or dementia is a prevalent neurocognitive disorder primarily affecting individuals over the age of 65. Identifying specific causes of AD and/or dementia can be challenging, with emerging evidence suggesting a potential association with autoimmune inflammatory conditions such as rheumatoid arthritis (RA). This study aimed to assess the prevalence rate of AD and/or
-
Development and Optimization of a Target Engagement Model of Brain IDO Inhibition for Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-01-26 Kurt R. Stover, Paul M. Stafford, Andreea C. Damian, Jagadeesh P. Pasangulapati, Jake Goodwin-Tindall, Lucía M. López Vásquez, Sanghyun Lee, Seung-Pil Yang, Mark A. Reed, Christopher J. Barden, Donald F. Weaver
Background: Indoleamine 2,3-dioxygenase (IDO1) inhibition is a promising target as an Alzheimer’s disease (AD) Disease-modifying therapy capable of downregulating immunopathic neuroinflammatory processes. Methods: To aid in the development of IDO inhibitors as potential AD therapeutics, we optimized a lipopolysaccharide (LPS) based mouse model of brain IDO1 inhibition by examining the dosedependent
-
Neuropharmacological Study on Capsaicin in Scopolamine-injected Mice Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-01-12 Sakshi Tyagi, Ajit Kumar Thakur
Aim:: To evaluate the potential beneficial role of Capsaicin in cognitive dysfunction, mitochondrial impairment, and oxidative damage induced by scopolamine in mice. Background:: Capsaicin is the chief phenolic component present in red chili and is responsible for its pungent and spicy flavor. It affects TRPV1 channels in nociceptive sensory neurons and is present in the hippocampus, and hypothalamus
-
Synapsin 1 Ameliorates Cognitive Impairment and Neuroinflammation in Rats with Alzheimer’s Disease: An Experimental and Bioinformatics Study Curr. Alzheimer Res. (IF 2.1) Pub Date : 2024-01-12 Wei Ma, Kui Lu, Hua-Min Liang, Jin-Yuan Zhang
Background::: Alzheimer’s disease (AD) is a persistent neuropathological injury that manifests via neuronal/synaptic death, age spot development, tau hyperphosphorylation, neuroinflammation, and apoptosis. Synapsin 1 (SYN1), a neuronal phosphoprotein, is believed to be responsible for the pathology of AD. Objective:: This study aimed to elucidate the exact role of SYN1 in ameliorating AD and its potential
-
Childhood Maltreatment and Dementia Risk Factors in Midlife: A Prospective Investigation Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-12-28 Cathy S. Widom, Hang H. Do, Kristin S. Lynch, Jennifer J. Manly
Background: Previous studies have linked childhood adversities to dementia risk, yet most studies are cross-sectional in design and utilize retrospective self-reports to assess childhood experiences. These design characteristics make it difficult to establish temporal order and draw firm conclusions. Objective: Using a longitudinal design, we sought to determine whether childhood maltreatment predicts
-
Uncovering the Impact of Aggrephagy in the Development of Alzheimer's Disease: Insights Into Diagnostic and Therapeutic Approaches from Machine Learning Analysis Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-12-21 Jiayu Xu, Siqi Gou, Xueyuan Huang, Jieying Zhang, Xuancheng Zhou, Xiangjin Gong, Jingwen Xiong, Hao Chi, Guanhu Yang
Background: Alzheimer's disease (AD) stands as a widespread neurodegenerative disorder marked by the gradual onset of memory impairment, predominantly impacting the elderly. With projections indicating a substantial surge in AD diagnoses, exceeding 13.8 million individuals by 2050, there arises an urgent imperative to discern novel biomarkers for AD. Methods: To accomplish these objectives, we explored
-
Interactions of Polyphenolic Gallotannins with Amyloidogenic Polypeptides Associated with Alzheimer’s Disease: From Molecular Insights to Physiological Significance Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-12-15 Jihane Khalifa, Steve Bourgault, Roger Gaudreault
Polyphenols are natural compounds abundantly found in plants. They are known for their numerous benefits to human health, including antioxidant properties and anti-inflammatory activities. Interestingly, many studies have revealed that polyphenols can also modulate the formation of amyloid fibrils associated with disease states and can prevent the formation of cytotoxic oligomer species. In this review
-
Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resveratrol in the Treatment of Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-12-01 Sian Jin, Xuefeng Guan, Dongyu Min
Background: To evaluate the efficacy and pharmacological mechanisms of resveratrol in Alzheimer’s disease (AD) patients. Methods: We conducted a thorough exploration of existing randomized controlled trials concerning the treatment of Alzheimer's disease patients using resveratrol, utilizing accessible open databases. Quantitative variables were represented as a standardized mean difference (SMD),
-
An Online Shared Decision-making Intervention for Dementia Prevention: A Parallel-group Randomized Pilot Study Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-12-01 Raymond L. Ownby, Rosemary Davenport
Objectives: Evaluate the acceptability and efficacy of an online dementia prevention intervention based on a cognitive behavioral shared decision-making model. Materials and Method: This was an unblinded pilot study in which participants were randomly assigned to one of two treatment groups. This study was carried out remotely via telephone, video conferencing, and online data collection. Eighteen
-
Blood Biomarkers Discriminate Cerebral Amyloid Status and Cognitive Diagnosis when Collected with ACD-A Anticoagulant Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-12-01 Zachary D. Green, Paul J. Kueck, Casey S. John, Jeffrey M. Burns, Jill K. Morris
Background: The development of biomarkers that are easy to collect, process, and store is a major goal of research on current Alzheimer’s Disease (AD) and underlies the growing interest in plasma biomarkers. Biomarkers with these qualities will improve diagnosis and allow for better monitoring of therapeutic interventions. However, blood collection strategies have historically differed between studies
-
Neuroimaging Genetics and Network Analysis in Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-11-10 Seok Woo Moon
The issue of the genetics in brain imaging phenotypes serves as a crucial link between two distinct scientific fields: neuroimaging genetics (NG). The articles included here provide solid proof that this NG link has considerable synergy. There is a suitable collection of articles that offer a wide range of viewpoints on how genetic variations affect brain structure and function. They serve as illustrations
-
The Association between Vitamin D Deficiency and Changes in Cognitive Functions in Chinese Older Adults: A Prospective Cohort Study Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-11-10 Tongtong Li, Chong Chen, Jing Yuan, Keming Zhang, Meilin Zhang, Huichao Zhao, Xiaomin Wu, Liping Zhu, Guowei Huang, Fei Ma
Background: Along with the problem of population aging, the prevalence of dementia is gradually increasing. Associations between vitamin D deficiency (VDD) and cognitive functions remain unclear. Objectives: We aimed to determine the relationship between VDD and changes in cognitive performance in community-dwelling older adults. Methods: In this longitudinal cohort study, participants aged ≥65 years
-
Alterations of Cerebral Blood Flow and its Connectivity Patterns Measured with Arterial Spin Labeling in Mild Cognitive Impairment Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-10-25 Mingjuan Qiu, Di Zhou, Haiyan Zhu, Yongjia Shao, Yan Li, Yibin Wang, Genlin Zong, Qian Xi
Objectives: Cerebral blood flow (CBF) is an important index for measuring brain function. Studies have shown that regional CBF changes inconsistently in mild cognitive impairment (MCI). Arterial spin labeling (ASL) is widely used in the study of CBF in patients with MCI. However, alterations in CBF connectivity in these patients remain poorly understood. Methods: In this study, 3D pseudo-continuous
-
Common Neuropsychiatric S ymptoms in Alzheimer’s Disease, Mild Cognitive Impairment, and Subjective Memory Complaints: A Unified Framework Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-10-23 Samuel L. Warren, Eid Abo Hamza, Richard Tindle, Edwina Reid, Paige Whitfield, Adam Doumit, Ahmed A. Moustafa
The Alzheimer’s disease (AD) continuum is a unique spectrum of cognitive impairment that typically involves the stages of subjective memory complaints (SMC), mild cognitive impairment (MCI), and AD dementia. Neuropsychiatric symptoms (NPS), such as apathy, anxiety, stress, and depression, are highly common throughout the AD continuum. However, there is a dearth of research on how these NPS vary across
-
Development of Computational Correlations among Known Drug Scaffolds and their Target-Specific Non-Coding RNA Scaffolds of Alzheimer's Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-10-20 Debjani Roy, Shymodip Kundu, Swayambhik Mukherjee
Background: Alzheimer's disease is the most common neurodegenerative disorder. Recent development in sciences has also identified the pivotal role of microRNAs (miRNAs) in AD pathogenesis. Objectives: We proposed a novel method to identify AD pathway-specific statistically significant miRNAs from the targets of known AD drugs. Moreover, microRNA scaffolds and corresponding drug scaffolds of different
-
Towards the Integrative Theory of Alzheimer’s Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis# Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-10-13 Yaroslav I. Molkov, Maria V. Zaretskaia, Dmitry V. Zaretsky
Introduction: A major gap in amyloid-centric theories of Alzheimer’s disease (AD) is that even though amyloid fibrils per se are not toxic in vitro, the diagnosis of AD clearly correlates with the density of beta-amyloid (Aβ) deposits. Based on our proposed amyloid degradation toxicity hypothesis, we developed a mathematical model explaining this discrepancy. It suggests that cytotoxicity depends on
-
Hybrid PET/MRI with Flutemetamol and FDG in Alzheimer's Disease Clinical Continuum Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-10-10 Lutfiye Ozlem Atay, Esen Saka, Umit Ozgur Akdemir, Ezgi Yetim, Erdem Balcı, Ethem Murat Arsava, Mehmet Akif Topcuoglu
Aims: We aimed to investigate the interaction between β -amyloid (Aβ) accumulation and cerebral glucose metabolism, cerebral perfusion, and cerebral structural changes in the Alzheimer's disease (AD) clinical continuum. Background: Utility of positron emission tomography (PET) / magnetic resonance imaging (MRI) hybrid imaging for diagnostic categorization of the AD clinical continuum including subjective
-
Innovative Discoveries in Neurosurgical Treatment of Neurodegenerative Diseases: A Narrative Review Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-28 Matthew C. Findlay, Majid Khan, Mrinmoy Kundu, Chase M. Johansen, Brandon Lucke-Wold
Neurodegenerative diseases (NDDs) encapsulate conditions in which neural cell populations are perpetually degraded and nervous system function destroyed. Generally linked to increased age, the proportion of patients diagnosed with a NDD is growing as human life expectancies rise. Traditional NDD therapies and surgical interventions have been limited. However, recent breakthroughs in understanding disease
-
Glial-derived Neuroinflammation induced with Amyloid-beta-peptide Plus Fibrinogen Injection in Rat Hippocampus Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-28 James G. McLarnon
Introduction: The present study has examined microglial and astrocyte activation in association with neuronal degeneration in an animal model using an injection of amyloid-beta peptide Aβ1-42 (Aβ42) plus fibrinogen into rat hippocampus. Methods: The combination of stimuli is suggested as a novel and potent perturbation to induce gliosis and the production of glial-derived neurotoxic factors in an animal
-
Early Chronic Stress Induced Changes within the Locus Coeruleus in Sporadic Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-26 Donné Minné, Jeanine L. Marnewick, Penelope Engel-Hills
: Chronic exposure to stress throughout the lifespan has been the focus of many studies on Alzheimer's disease (AD) because of the similarities between the biological mechanisms involved in chronic stress and the pathophysiology of AD. In fact, the earliest abnormality associated with the disease is the presence of phosphorylated tau protein in locus coeruleus neurons, a brain structure highly responsive
-
Behavioural Variant Frontotemporal Dementia due to CCNF Gene Mutation: A Case Report Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-26 Feng-Ling You, Gao-Fu Xia, Jing Cai
Background: Frontal, temporal lobe dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative diseases. Studies have found that CCNF mutations have been found in patients with familial and sporadic ALS and FTD. Behavioural variant frontotemporal dementia (bvFTD) is a clinical syndrome characterized by progressive deterioration of personality, social behaviour, and cognitive
-
Early Detection of Dementia using Risk Classification in MCI: Outcomes of Shanghai Mild Cognitive Impairment Cohort Study Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-26 Bin Zhou, Qianhua Zhao, Shinsuke Kojima, Ding Ding, Satoshi Higashide, Masanori Fukushima, Zhen Hong
Introduction: The purpose of this study is to identify the risk factors and risk classification associated with the conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia to facilitate early intervention and the design of clinical trials for AD. Methods: The study comprised a prospective cohort study of 400 subjects with MCI who had annual follow-ups for 3 years. Results:
-
T Lymphocytes in the Pathogenesis and Progression of Alzheimer’s Disease: Pursuing Direct Neuropathological Evidence Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-26 Peng Cheng Han, Eric Daniel Hamlett
Multiple studies have proposed important roles of T cells in the pathogenesis of Alzheimer’s disease. Given the successful application of immune-based therapy for cancer and a variety of diseases, T cell-modifying therapy becomes an attractive way to develop new therapies for Alzheimer’s disease and perhaps neurodegenerative diseases in general. However, most of these studies address peripheral T cell
-
Predicting Dementia Due to Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Algorithms with the Addenbrooke’s Cognitive Examination-Revised Subscores Combined with Sociodemographic Factors Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-21 Viviane Amaral-Carvalho, Thais Bento Lima-Silva, Luciano Inácio Mariano, Leonardo Cruz de Souza, Henrique Cerqueira Guimarães, Valeria Santoro Bahia, Ricardo Nitrini, Maira Tonidandel Barbosa, Mônica Sanches Yassuda, Paulo Caramelli
Background: Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD) are important causes of dementia with challenging differential diagnoses in many cases. Addenbrooke’s Cognitive Examination-Revised (ACE-R) is a cognitive battery that may be useful to differentiate the two disorders. Objective: The objectibe of this study is to investigate the value of the ACE-R combined with
-
MicroRNA-125a-3p Modulate Amyloid β-Protein through the MAPK Pathway in Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-22 Xi-Chen Zhu, Meng-Zhuo Zhu, Jing Lu, Qing-Yu Yao, Jia-Wei Hu, Wen-Jun Long, Sha-Sha Ruan, Wen-Zhuo Dai, Rong Li
Background: MicroRNA (miR)-125a-3p is reported to play an important role in some central nervous system diseases, such as Alzheimer’s disease (AD). However, a study has not been conducted on the mechanism of miR-125a-3p in the pathological process of AD. Methods: First, we assessed the expression of miR-125a-3p in AD cohort. Subsequently, we altered the expressions of miR-125a-3p to assess its role
-
Neuropsychiatric Symptoms and Trajectories of Dependence and Cognition in a Sample of Community-dwelling Older Adults with Dementia Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-22 Anton J. Kociolek, Kayri K. Fernandez, Michelle Hernandez, Zhezhen Jin, Stephanie Cosentino, Carolyn W. Zhu, Yian Gu, Davangere P. Devanand, Yaakov Stern
Background and Objectives: Neuropsychiatric symptoms (NPS), including psychotic symptoms (hallucinations, illusions, delusions), agitation/aggression, and depressed mood, are common in individuals with Alzheimer’s disease (AD) and predict poorer outcomes, including faster disease progression. We aimed to evaluate associations between NPS and cognition and dependence in a multi-ethnic sample of community-dwelling
-
Acupuncture Improves Synaptic Plasticity of SAMP8 Mice through the RhoA/ROCK Pathway Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-11 Bohong Kan, Zhengjia Dong, Zhenyu Tang, Lan Zhao, Zhen Li
Background: Studies have found synaptic plasticity damage to be an early marker of Alzheimer's disease (AD). RhoA/ROCK pathway is involved in the regulation of synaptic plasticity. Acupuncture can significantly improve the cognitive state of AD. Objective: We aimed to use modern biological technology to detect the changes in synaptic plasticity and RhoA/ROCK pathway in SAMP8 mice, as well as the intervention
-
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-11 Faruk Kurhan, Mustafa Akın
Alzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer’s disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved
-
Amisulpride Decreases Tau Protein Hyperphosphorylation in the Brain of OXYS Rats Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-11 Camilla A. Molobekova, Elena M. Kondaurova, Tatiana V. Ilchibaeva, Alexander Ya. Rodnyy, Natalia A. Stefanova, Nataliya G. Kolosova, Vladimir S. Naumenko
Aim: In this study, OXYS rats of three ages (1, 3, and 6 months), a proven model of Alzheimer’s disease (AD), at various stages of disease progression were used to thoroughly study the effects of amisulpride on behavior and tau protein phosphorylation. Background: With the growing number of patients with AD, the problem of finding a cure is very acute. Neurodegeneration in AD has various causes, one
-
Alterations in Peripheral Metabolites as Key Actors in Alzheimer’s Disease Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-11 Can Sheng, Xu Chu, Yan He, Qingqing Ding, Shulei Jia, Qiguang Shi, Ran Sun, Li Song, Wenying Du, Yuan Liang, Nian Chen, Yan Yang, Xiaoni Wang
Growing evidence supports that Alzheimer’s disease (AD) could be regarded as a metabolic disease, accompanying central and peripheral metabolic disturbance. Nowadays, exploring novel and potentially alternative hallmarks for AD is needed. Peripheral metabolites based on blood and gut may provide new biochemical insights about disease mechanisms. These metabolites can influence brain energy homeostasis
-
Multiple Sensory Impairments in Relation to Cognitive Function: Two Nationwide Cross-sectional Studies Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-07 Binghan Wang, Hui Chen, Jie Shen, Wansi Zhong, Yan Zheng, Min Lou, Lusha Tong, Changzheng Yuan
Introduction: Sensory impairments (SIs, including visual, hearing, olfactory, and taste impairments) have been individually associated with age-related cognitive function. Little is known regarding their combined associations with cognitive function. Methods: We included 2,931 participants (mean age of 69.1 years) from the National Health and Nutrition Examination Survey (NHANES, 2011-2014) and 10
-
Neuroprotection of Thioredoxin1 in the Brain Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-07 Roxana Noriega-Navarro, Ricardo J. Martínez-Tapia, Juan L. Osornio-Hernández, Lucia Landa-Navarro, Luis O. Xinastle-Castillo, Abraham Landa, Luz Navarro
Thioredoxin1 (Trx1) is a ubiquitous antioxidant protein that regulates the cell's redox status. Trx1's thiol redox activity protects neurons from various physiological processes that cause neuronal damage and neurodegeneration, including oxidative stress, apoptosis, and inflammation. Several studies have found that direct or indirect Trx1 regulation has neuroprotective effects in the brain, protecting
-
Neural Oscillation Disorder in the Hippocampal CA1 Region of Different Alzheimer's Disease Mice Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-09-06 Weiming Yuan, Weijia Zhi, Lizhen Ma, Xiangjun Hu, Qian Wang, Yong Zou, Lifeng Wang
Background: Alzheimer's disease (AD) is a well-known neurodegenerative disease that gradually induces neural network dysfunction and progressive memory deficits. Neural network activity is represented by rhythmic oscillations that influence local field potentials (LFPs). However, changes in hippocampal neural rhythmic oscillations in the early stage of AD remain largely unexplored. Objective: This
-
Effect of Transcranial Pulse Stimulation for the Treatment of Alzheimer´s Disease and its Related Symptoms Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-08-08 Ramiro Fernández-Castaño, Miguel Ángel Fernández-Blázquez, Iria Echevarría Fernández, Manuela Cabrera-Freitag, Karin Freitag
Alzheimer's disease (AD) is the most common cause of neurodegenerative cognitive impairment. Brain stimulation techniques based on the delivery of transcranial shockwaves are currently being studied for their increasing popularity as an approach to modulate the human brain in a focal and targeted manner making this therapy a promising line of action against AD. In the present manuscript, we review
-
Amyloid-β-Induced Transglutaminase 2 Expression and Activities are Modulated by 2-Pentadecyl-2-Oxazoline in Mouse and Human Microglial Cell Lines Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-08-08 Andrea Parente, Rosa Giacca, Roberta Arena, Ilenia Rullo, Francesca Guida, Sabatino Maione, Vittorio Gentile
Background: Transglutaminase 2 is an ubiquitously multifunctional enzyme and the most widely studied of the transglutaminase family. Consistent with its role in promoting post-translational modifications of proteins, Transglutaminase 2 is involved in many physiological processes such as apoptosis, signal transduction, and cellular adhesion. Several findings indicate that Transglutaminase 2 plays a
-
Different Patterns of Locus Coeruleus MRI Alteration in Alzheimer’s and Dementia with Lewy Bodies Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-08-01 Alessandro Galgani, Giovanni Palermo, Francesco Lombardo, Nicola Martini, Luca Bastiani, Andrea Vergallo, Luca Tommasini, Gabriele Bellini, Filippo Baldacci, Daniela Frosini, Gloria Tognoni, Marco Gesi, Filippo Cademartiri, Francesco Fornai, Nicola Pavese, Roberto Ceravolo, Filippo Sean Giorgi
Background: The integrity of Locus Coeruleus can be evaluated in vivo using specific Magnetic Resonance Imaging sequences. While this nucleus has been shown to be degenerated both in post-mortem and in vivo studies in Alzheimer’s Disease, for other neurodegenerative dementias such as Dementia with Lewy Bodies this has only been shown ex-vivo. Objective: To evaluate the integrity of the Locus Coeruleus
-
Perturbations in Microbiota Composition as a Novel Mediator in Neuropsychiatric, Neurological and Mental Disorders: Preventive and Therapeutic Complementary Therapies to Balance the Change Curr. Alzheimer Res. (IF 2.1) Pub Date : 2023-08-01 Majid Taati Moghadam, Andrés Alexis Ramírez-Coronel, Samaneh Darijani, Majid Reza Akbarizadeh, Mahin Naderifar, Simin Soltaninejad, Shahla Shahbazi, Amin Sadeghi Dousari, Ali Mojtahedi, Reza Akhavan-Sigari
Although microbiology and neurology are separate disciplines, they are linked to some infectious and neurological diseases. Today, microbiome is considered as one of the biomarkers of health by many researchers. This has led to the association of microbiome changes with many neurological diseases. The natural microbiota has many beneficial properties. If disrupted and altered, it can lead to irreversible